To verify the clinical value of CPA4, an ROC curve analysis was performed to verify the clinical value of CPA4 in the diagnosis of BLCA; our results showed that CPA4 may be a potential diagnostic biomarker between bladder cancer and normal tissues, with an AUC of 0.798 (Figure 2d). Here, CPA4 is linked to urinary bladder cancer.